

## **ACP Approves a Recommendation From The Immunization Committee To Endorse The Interim ACIP Recommendations For Use Of Additional Dose Of Pfizer Or Moderna COVID-19 Vaccine Among Immunocompromised Persons**

**Approved by the Executive Committee of the Board of Regents on Aug. 16, 2021**

### **Background:**

Each year, the Advisory Committee on Immunization Practices (ACIP) reviews and publishes the recommended adult immunization schedule for adults age 19 and older. In November 2020, the Executive Committee of the Board of Regents (ECBOR) approved the 2021 ACIP Recommended Immunization Schedule for Adults, which was published in *Annals* in March 2021. The ECBOR has also voted to support interim ACIP recommendations for use of [Pfizer-BioNTech](#), [Moderna](#), and [Janssen](#) COVID-19 vaccines under the FDA's Emergency Use Authorization (EUA).

The ACIP convened an emergency meeting on August 13, 2021 to review and vote on recommendations for use of an additional dose of mRNA COVID-19 vaccine following a primary series among immunocompromised people. ACIP voted 11-0 to approve the following interim recommendation:

*An additional dose of Pfizer-BioNTech COVID-19 vaccine ( $\geq 12$  years) or Moderna COVID-19 vaccine ( $\geq 18$  years) is recommended following a primary series in immunocompromised people under the FDA's Emergency Use Authorization.*

ACP's Immunization Committee (IC) convened on Monday, August 16, 2021 by video conference to discuss the new ACIP interim recommendations. IC members in attendance included Vidya Sundareshan, MD, FACP (Chair); Jason Goldman, MD, FACP; Saba Hasan, MD, FACP; Josune Iglesias, MD, FACP; Susan Lee, MD, FACP; and Kristin Mitchell, MD, FACP.

IC members in attendance vote unanimously to support the ACIP interim recommendations. Michael Bronze, MD, MACP was unable to attend the meeting but provided his support of the recommendations by email.

The IC recommends that the ECBOR support ACIP interim recommendations for use of an additional dose of Pfizer-BioNTech or Moderna COVID-19 vaccine following a primary series in immunocompromised people under the FDA's EUA.